

Chul Won Jung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5016825/publications.pdf>

Version: 2024-02-01

129
papers

1,387
citations

361413

20
h-index

434195

31
g-index

132
all docs

132
docs citations

132
times ranked

2702
citing authors

#	ARTICLE	IF	CITATIONS
1	The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients. <i>Leukemia Research</i> , 2022, 114, 106791.	0.8	0
2	How myeloproliferative neoplasms patients'™ experience and expectations differ from physicians'™: the international MPN Landmark survey. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 444-454.	1.7	2
3	Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea. <i>Blood Research</i> , 2022, , .	1.3	2
4	A case of tuberculosis meningitis after allogeneic hematopoietic stem cell transplantation for relapsed Acute Myeloid Leukemia. <i>Transplant Infectious Disease</i> , 2021, 23, e13482.	1.7	3
5	Association between body image dissatisfaction and poor quality of life and depression among patients with hematopoietic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2021, 29, 3815-3822.	2.2	10
6	Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 413-423.	1.7	4
7	Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey. <i>Blood Research</i> , 2021, 56, 31-37.	1.3	2
8	Is the New Interferon-Gamma Releasing Assay Beneficial for the Diagnosis of Latent and Active Mycobacterium tuberculosis Infections in Tertiary Care Setting?. <i>Journal of Clinical Medicine</i> , 2021, 10, 1376.	2.4	10
9	Recurrent somatic mutations and low germline predisposition mutations in Korean ALL patients. <i>Scientific Reports</i> , 2021, 11, 8893.	3.3	4
10	Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3. <i>Leukemia Research</i> , 2021, 105, 106578.	0.8	0
11	Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric <sc>CD34</sc> ⁺ cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2021, 36, 737-749.	1.3	2
12	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. <i>HemaSphere</i> , 2021, 5, e617.	2.7	10
13	Complementary Use of Prosepsin with the Sepsis-3 Criteria Improved Identification of High-Risk Patients with Suspected Sepsis. <i>Biomedicines</i> , 2021, 9, 1076.	3.2	5
14	The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 45-62.	1.7	13
15	Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 194-204.	1.7	6
16	Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients. <i>Leukemia Research</i> , 2021, 111, 106728.	0.8	1
17	Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea. <i>Blood Research</i> , 2021, , .	1.3	3
18	Therapy-related myeloid neoplasms after transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>Blood Research</i> , 2021, 56, 349-353.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level. <i>Mycoses</i> , 2020, 63, 89-94.	4.0	17
20	Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults. <i>Annals of Laboratory Medicine</i> , 2020, 40, 88-91.	2.5	1
21	Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B cell phenotype Burkitt leukemia with IGH μ MYC rearrangement. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 255-260.	2.8	4
22	Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23064.	2.1	5
23	Inducing Transient Mixed Chimerism for Allograft Survival Without Maintenance Immunosuppression With Combined Kidney and Bone Marrow Transplantation: Protocol Optimization. <i>Transplantation</i> , 2020, 104, 1472-1482.	1.0	29
24	Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 2310.	2.4	1
25	Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia. <i>Scientific Reports</i> , 2020, 10, 14297.	3.3	22
26	Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. <i>Blood Advances</i> , 2020, 4, 2032-2043.	5.2	38
27	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , 2020, 17, e1003091.	8.4	9
28	Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners. <i>Patient Education and Counseling</i> , 2020, 103, 1630-1636.	2.2	6
29	TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. <i>British Journal of Haematology</i> , 2020, 190, 869-876.	2.5	40
30	HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study. <i>Blood</i> , 2020, 136, 1-1.	1.4	2
31	Clonal dominance of a donor-derived del(20q) clone after allogeneic hematopoietic stem cell transplantation in an acute myeloid leukemia patient with del(20q). <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22951.	2.1	7
32	Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2019, 110, 709-722.	1.6	6
33	Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. <i>Lancet Haematology</i> , the, 2019, 6, e562-e572.	4.6	30
34	Anti-leukemic effects of simvastatin on NRASG12D mutant acute myeloid leukemia cells. <i>Molecular Biology Reports</i> , 2019, 46, 5859-5866.	2.3	12
35	Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). <i>Bone Marrow Transplantation</i> , 2019, 54, 1361-1368.	2.4	20
36	Hereditary platelet function disorder from <i>RASGRP2</i> gene mutations encoding CalDAG-GEFI identified by whole-exome sequencing in a Korean woman with severe bleeding. <i>Haematologica</i> , 2019, 104, e274-e276.	3.5	9

#	ARTICLE	IF	CITATIONS
37	Different prognostic effects of core-binding factor positive AML with Korean AML registry data. <i>Annals of Hematology</i> , 2019, 98, 1135-1147.	1.8	9
38	HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1439-1450.	7.2	14
39	Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2018, 97, 955-965.	1.8	3
40	A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome ⁺ positive chronic myeloid leukemia in chronic phase: <sc>ENESTK</sc>orea. <i>Cancer Medicine</i> , 2018, 7, 1814-1823.	2.8	10
41	Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. <i>Bone Marrow Transplantation</i> , 2018, 53, 967-976.	2.4	14
42	Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	37
43	Poor Prognostic Implication of <i>ASXL1</i> Mutations in Korean Patients With Chronic Myelomonocytic Leukemia. <i>Annals of Laboratory Medicine</i> , 2018, 38, 495-502.	2.5	5
44	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. <i>Oncotarget</i> , 2018, 9, 4961-4968.	1.8	19
45	A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine. <i>Oncotarget</i> , 2018, 9, 6607-6614.	1.8	7
46	Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 7180-7188.	7.0	57
47	Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma. <i>Nutrition</i> , 2017, 36, 67-71.	2.4	20
48	5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 8305-8314.	1.8	6
49	Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 890-899.	1.7	17
50	Clinical manifestation and prognostic features of extramedullary plasmacytomas.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19516-e19516.	1.6	1
51	Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab. <i>Blood Research</i> , 2016, 51, 297.	1.3	2
52	Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 1061-1070.	2.1	0
53	Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , 2016, 73, 496-505.	3.3	34
54	High frequency of <i>JAK2</i> exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance. <i>Journal of Clinical Pathology</i> , 2016, 69, 737-741.	2.0	8

#	ARTICLE	IF	CITATIONS
55	Cytogenetic profiles of 2806 patients with acute myeloid leukemia—a retrospective multicenter nationwide study. <i>Annals of Hematology</i> , 2016, 95, 1223-1232.	1.8	14
56	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. <i>Annals of Hematology</i> , 2016, 95, 625-635.	1.8	15
57	Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. <i>Journal of Translational Medicine</i> , 2016, 14, 82.	4.4	9
58	Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. <i>Annals of Hematology</i> , 2016, 95, 325-335.	1.8	36
59	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. <i>Annals of Hematology</i> , 2016, 95, 301-310.	1.8	26
60	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 61-70.	2.0	43
61	Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of <i>DNMT3A</i> mutations. <i>Oncotarget</i> , 2016, 7, 54825-54837.	1.8	22
62	Measurement of Quality of Life and Depression of Spouse Caregivers for Survivors after Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 4775-4775.	1.4	0
63	Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2016, 128, 4938-4938.	1.4	0
64	Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2016, 128, 2876-2876.	1.4	0
65	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. <i>Haematologica</i> , 2015, 100, e351-e353.	3.5	31
66	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 746-756.	1.4	160
67	Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 1013-1020.	4.1	37
68	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015, 35, 2363-2369.	3.9	21
69	Guidelines for the management of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 771-788.	1.7	22
70	<i>BRAF</i> V600E and <i>MAP2K1</i> Mutations in Hairy Cell Leukemia and Splenic Marginal Zone Lymphoma Cases. <i>Annals of Laboratory Medicine</i> , 2015, 35, 257-259.	2.5	6
71	Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. <i>Oncotarget</i> , 2015, 6, 42803-42812.	1.8	23
72	Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2067-2074.	1.3	25

#	ARTICLE	IF	CITATIONS
73	KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study. <i>Human Immunology</i> , 2015, 76, 636-643.	2.4	11
74	Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial. <i>Blood</i> , 2015, 126, 476-476.	1.4	9
75	Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7044-7044.	1.6	22
76	Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients. <i>Oncotarget</i> , 2015, 6, 16653-16662.	1.8	17
77	Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib. <i>Blood</i> , 2015, 126, 4053-4053.	1.4	0
78	Survey of QoL (quality of life) on Patients Receiving Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Korean CML Working Party Group. <i>Blood</i> , 2015, 126, 5166-5166.	1.4	1
79	Dyadic Concordance of Sexuality Among Hematopoietic Stem Cell Transplantation Patients and Their Partners. <i>Blood</i> , 2015, 126, 4349-4349.	1.4	0
80	Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients. <i>Blood</i> , 2015, 126, 1904-1904.	1.4	0
81	Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2015, 126, 5160-5160.	1.4	0
82	Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome. <i>Anticancer Research</i> , 2015, 35, 3081-9.	1.1	25
83	Prevention of Venous Thromboembolism, 2nd Edition: Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice Guidelines. <i>Journal of Korean Medical Science</i> , 2014, 29, 164.	2.5	55
84	Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	18
85	Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: Fludarabine versus cyclophosphamide-ATG. <i>Leukemia Research</i> , 2014, 38, 730-736.	0.8	2
86	Clinical relevance of genetic mutations on treatment response to the demethylating agents in myelodysplastic syndromes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7115-7115.	1.6	0
87	Evaluation of biochemical features of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20698-e20698.	1.6	1
88	An Adverse Prognostic Effect of Homozygous TET2 Mutational Status on the Relapse Risk of Acute Myeloid Leukemia Patients of Normal Karyotype. <i>Blood</i> , 2014, 124, 1052-1052.	1.4	0
89	Treatment Outcome and Prognostic Factors of Korean Patients with Chronic Lymphocytic Leukemia: Multicenter Retrospective Study. <i>Blood</i> , 2014, 124, 5669-5669.	1.4	0
90	Long-Term Follow-up of Continuous Imatinib Plus Combination Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3654-3654.	1.4	0

#	ARTICLE	IF	CITATIONS
91	A Prospective Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition of Antithymocyte Globuline for Allogeneic Hematopoietic Cell Transplantation in Patients with Adult Severe Aplastic Anemia; Interim Analysis. <i>Blood</i> , 2014, 124, 3890-3890.	1.4	0
92	Renal Insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. <i>Anticancer Research</i> , 2014, 34, 4299-306.	1.1	10
93	Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome. <i>Blood Research</i> , 2013, 48, 68.	1.3	2
94	A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Postâ€“Polycythemia Vera MF (PPV-MF), Or Postâ€“Essential Thrombocythemia MF (ET-MF). <i>Blood</i> , 2013, 122, 4086-4086.	1.4	12
95	Will JAK1/2 inhibitors change the standard of care for myelofibrosis?. <i>The Korean Journal of Hematology</i> , 2012, 47, 241.	0.7	1
96	Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2011, 93, 383-388.	1.6	21
97	Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 Study. <i>Blood</i> , 2011, 118, 1517-1517.	1.4	6
98	Genome-Wide Single-Nucleotide Polymorphism-Array Can Improve Prognostic Stratification of Core Binding Factor Acute Myeloid Leukemia, Especially in the Subgroup with Inv(16)/t(16;16) or without D816 C-KIT Mutation,. <i>Blood</i> , 2011, 118, 3515-3515.	1.4	0
99	Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study,. <i>Blood</i> , 2011, 118, 3424-3424.	1.4	0
100	Hepatic Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acquired Aplastic Anemia. <i>Blood</i> , 2011, 118, 3012-3012.	1.4	0
101	Baseline Quality of Life Assessed with the EORTC QLQ-C30 Predicts the Treatment Outcome of Patients with Diffuse Large B-Cell Lymphoma: Results of a Prospective Cohort Study. <i>Blood</i> , 2011, 118, 1595-1595.	1.4	0
102	Addition of Hemoglobin Level Into the Prognostic Scoring System Together with White Blood Cell and Platelet Count Provides Better Prognostic Stratification for Overall Survival, Complete Remission Rate and Early Death, but Not for the Relapse Risk in Adult Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2011, 118, 4898-4898.	1.4	0
103	Multicenter Retrospective Study on the Development of Peripheral Lymphocytosis During Second-Line Dasatinib Therapy for Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 2275-2275.	1.4	1
104	Genome-Wide Single-Nucleotide Polymorphism-Array Based Karyotyping Detects Clonal Aberrations, and Predicts the Risk of Imatinib Failure In Chronic Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 3387-3387.	1.4	0
105	Trough Plasma Imatinib Levels and ABCG2 Polymorphisms Are Correlated with Optimal Cytogenetic Responses at 6 Months After Treatment with Standard Dose of Imatinib In Newly Diagnosed CML. <i>Blood</i> , 2010, 116, 2272-2272.	1.4	0
106	Genome-Wide Single-Nucleotide Polymorphism-Array Based Karyotyping Detects Clonal Aberrations Including Uniparental Disomy (UPD), Gain or Loss Which Were Unfavorable Prognostic Factor In Acute Myeloid Leukemia with Normal Karyotype.. <i>Blood</i> , 2010, 116, 1669-1669.	1.4	8
107	A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 mri.. <i>Blood</i> , 2010, 116, 1125-1125.	1.4	0
108	A 2-Year Single Center Experience of Decitabine Treatment for the Patients with MDS and CMML. <i>Blood</i> , 2010, 116, 4952-4952.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Dasatinib for Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib In Korean Patients.. Blood, 2010, 116, 4494-4494.	1.4	0
110	Secondary Acute Myeloid Leukemia (AML), Including Therapy-Related AML, Associates with Worse Treatment Outcomes, Than De Novo AML Even After Hematopoietic Stem Cell Transplantation, and Its Unfavorable Behavior Does Not Associated with Functional Activity of p-Glycoprotein, MDR1. Blood, 2010, 116, 2157-2157.	1.4	0
111	Addition of Hemoglobin Level Into the Prognostic Scoring System Together with White Blood Cell and Platelet Count Provides Better Prognostic Stratification for Treatment-Related Mortality and Overall Survival, but Not for Relapse Risk In Adult Patients with Acute Promyelocytic Leukemia. Blood, 2010, 116, 4371-4371.	1.4	0
112	Pharmacogenomics-Based Drug Response Prediction Model for Acute Myeloid Leukemia with Normal Karyotype. Blood, 2010, 116, 2698-2698.	1.4	0
113	The Prognostic Utility of the Simplified Acute Physiology Score II (SAPS II) and the Sequential Organ Failure Assessment (SOFA) Score for Hemato-Oncology Patients Admitted to the Intensive Care Unit. The Korean Journal of Critical Care Medicine, 2009, 24, 4.	0.2	1
114	Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.. Blood, 2009, 114, 4661-4661.	1.4	0
115	Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea.. Blood, 2009, 114, 4298-4298.	1.4	0
116	Single Nucleotide Polymorphism (SNP) Approach of Multiple Candidate Pathways Predicting the Risk of Acute / Chronic Graft-Versus-Host Disease or Transplant Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: Potential Involvement of Nuclear Factor Kappa-B (NFkB), Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor-Beta (TGF- β) Pathway with Chronic Graft-Versus-Host Disease Graft-Versus-Host Disease.. Blood, 2009, 114, 2221-2221.	1.4	0
117	Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia.. Blood, 2009, 114, 1110-1110.	1.4	8
118	A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 MRI. Blood, 2008, 112, 3649-3649.	1.4	4
119	Natural Killer (NK) or NK/T Cell Lineage Large Granular Lymphocytosis Associated with Dasatinib Therapy for Philadelphia Chromosome Positive Leukemia.. Blood, 2008, 112, 933-933.	1.4	2
120	Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia?. Blood, 2008, 112, 4219-4219.	1.4	0
121	Neutrophil Counts Could Predict the Response to Immunosuppressive Treatment with Antithymocyte Globulin and Cyclosporine in the Patients with Severe Aplastic Anemia. Blood, 2008, 112, 4109-4109.	1.4	8
122	BCL2 Gene Polymorphism Could Predict the Treatment Outcomes in Patients with De Novo Acute Myeloid Leukemia. Blood, 2008, 112, 3973-3973.	1.4	0
123	The Clinical Guidelines for Myelodysplastic Syndrome. The Korean Journal of Hematology, 2007, 42, 71.	0.7	1
124	Generation and Qualification of Functionally Active Leukemia-derived DCs from Malignant Blasts in Acute Leukemia. The Korean Journal of Hematology, 2007, 42, 264.	0.7	0
125	The Optimal Processing Time of Adipose-Derived Mesenchymal Stem Cell after Lipoaspiration.. Blood, 2007, 110, 4107-4107.	1.4	0
126	Allogeneic Hematopoietic Cell Transplantation (HCT) for Acute Leukemia in First Relapse or Second Remission.. Blood, 2005, 106, 5415-5415.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Tuberculosis in Hematopoietic Stem Cell Transplant Recipients in Korea. International Journal of Hematology, 2004, 79, 185-188.	1.6	36
128	Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA. American Journal of Hematology, 2004, 75, 121-127.	4.1	9
129	Erythropoietin Response Is Inadequate in Cancer Patients Receiving Chemotherapy. International Journal of Hematology, 2001, 74, 416-420.	1.6	6